Action of cilostazol in diabetic and non-diabetic rats as prevention of atherosclerosis
DOI:
https://doi.org/10.33448/rsd-v12i4.40968Keywords:
Cilostazol; Atherosclerosis; Diabetes mellitus.Abstract
Atherosclerosis is a chronic inflammatory disease of multifactorial origin that occurs in response to endothelial aggression, affecting mainly the intimal layer of medium and large arteries. Type 2 diabetes mellitus is associated with a high rate of atherosclerotic cardiovascular disease. This study aims to analyze the impact, by drug treatment of Cilostazol, which is an antiplatelet drug, on the reduction of the aortic artery thickness of rats induced to develop diabetes through the administration of streptozotocin, compared to a control group without diabetes. The study showed that the time it took for the rat to develop diabetes was 8 weeks, the rats in the group that was administered streptozotocin showed a significant increase in aortic arterial thickness, especially in the intimal layer of the artery. A reduction in the thickness of the intimal layer of the aorta arteries of the rats submitted to treatment with cilostazol was observed, with significant significance when comparing the groups with diabetes and even when comparing the rats that were not induced to diabetes, showing that cilostazol can be a great ally in preventing atherosclerosis.
References
Amarante, R., Castro, R., Lage, A., & Cisternas, J. (2007). Diabetes Mellitus como fator de risco na aterogênese. Arq Med Hosp Fac Cienc Med Santa Casa São Paulo, 52(3), 87–93.
Andreollo, N. A., Santos, E. F. dos, Araújo, M. R., & Lopes, L. R. (2012). Idade dos ratos versus idade humana: qual é a relação? ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo), 25(1), 49–51. https://doi.org/10.1590/s0102-67202012000100011
Bahia, L., Guilherme, L., Aguiar, K., Villela, N. R., Bottino, D., & Bouskela, E. (2004). Endotélio e aterosclerose. Revista Da SOCERJ, 17, 26–32.
Bangalore, S., Singh, A., Toklu, B., DiNicolantonio, J. J., Croce, K., Feit, F., & Bhatt, D. L. (2014). Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: Insights from a meta-analysis of randomised trials. Open Heart, 1(1), 1–18. https://doi.org/10.1136/openhrt-2014-000068
Chapman, T. M., & Goa, K. L. (2003). Cilostazol. American Journal of Cardiovascular Drugs, 3(2), 117–138. https://doi.org/10.2165/00129784-200303020-00006
Cilostazol. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. (n.d.). PubMed. (2017). 450(Md), 1–5.
Delfino, V. D., Figueiredo, J. F., Matsuo, T., Favero, M. E., Matni, A. M., & Mocelin, A. (2002). Diabetes mellitus induzido por estreptozotocina: comparaçäo em longo prazo entre duas vias de administraçäo. J. Bras. Nefrol., 24(1), 31–36.
Furman, B. L. (2015). Streptozotocin-Induced Diabetic Models in Mice and Rats. Current Protocols in Pharmacology, 70, 5.47.1-5.47.20. https://doi.org/10.1002/0471141755.ph0547s70
Hong, S., Nam, M., Little, B., Paik, S., Lee, K., Woo, J., & vessels, D. K.-H., 2019, undefined. (n.d.). Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness. Springer. https://link.springer.com/article/10.1007/s00380-019-01421-1
Hotta, V. T., Rangel, D. D. do N., Tavares, G. M. P., Mangini, S., & Lemos, P. A. (2017). Diagnosis and treatment of rare complication after endomyocardial biopsy. Arquivos Brasileiros de Cardiologia, 109(6), 618–619. https://doi.org/10.5935/abc.20170120
Induce, F. T., & Atherogenesis, I. O. R. (2008). Inflammation or Atherogenesis. Health (San Francisco), 115–126.
Jung, K. I., Kim, J. H., Park, H. Y. L., & Park, C. K. (2013). Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. Journal of Pharmacology and Experimental Therapeutics, 345(3), 457–463. https://doi.org/10.1124/jpet.113.203067
Junod, A., Lambert, A. E., Orci, L., Pictet, R., Gonet, A. E., & Renold, A. E. (1967). Studies of the Diabetogenic Action of Streptozotocin. Proceedings of the Society for Experimental Biology and Medicine, 126(1), 201–205. https://doi.org/10.3181/00379727-126-32401
Junod, A., Lambert, A. E., Stauffacher, W., & Renold, A. E. (1969). Diabetogenic action of streptozotocin: relationship of dose to metabolic response. The Journal of Clinical Investigation, 48(11), 2129–2139. https://doi.org/10.1172/JCI106180
Kolb, H. (1987). Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes/Metabolism Reviews, 3(3), 751–778. https://doi.org/10.1002/dmr.5610030308
Lee, D. H., Chun, E. J., Oh, T. J., Kim, K. M., Moon, J. H., Choi, S. H., Park, K. S., Jang, H. C., & Lim, S. (2019). Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study. Diabetes, Obesity and Metabolism, 21(6), 1409–1418. https://doi.org/10.1111/dom.13667
Lee, J. H., Oh, G. T., Park, S. Y., Choi, J. H., Park, J. G., Kim, C. D., Lee, W. S., Rhim, B. Y., Shin, Y. W., & Hong, K. W. (2005). Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-α formation in low-density lipoprotein receptor-null mice fed high cholesterol. Journal of Pharmacology and Experimental Therapeutics, 313(2), 502–509. https://doi.org/10.1124/jpet.104.079780
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019). Atherosclerosis. Nature Reviews Disease Primers, 5(1), 1–18. https://doi.org/10.1038/s41572-019-0106-z
Omi, H., Okayama, N., Shimizu, M., Fukutomi, T., Nakamura, A., Imaeda, K., Okouchi, M., & Itoh, M. (2004). Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Microvascular Research, 68(2), 119–125. https://doi.org/10.1016/j.mvr.2004.05.002
Park, J.-S., & Kim, Y.-J. (2008). The Clinical Effects of Cilostazol on Atherosclerotic Vascular Disease. REVIEW Korean Circ J, 38, 441–445. https://synapse.koreamed.org/upload/SynapseData/PDFData/0054KCJ/kcj-38-441.pdf
Rakieten, N., Rakieten, M. L., & Nadkarni, M. V. (1963). Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemotherapy Reports, Rep. 1963 May; 29, 91–98.
Rogers, K. C., Oliphant, C. S., & Finks, S. W. (2015). Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature. Drugs, 75(4), 377–395. https://doi.org/10.1007/s40265-015-0364-3
Sallustio, F., Rotondo, F., Di Legge, S., & Stanzione, P. (2010). Cilostazol in the Management of Atherosclerosis. Current Vascular Pharmacology, 8(3), 363–372. https://doi.org/10.2174/157016110791112331
Santos, M. G. dos, Pegoraro, M., Sandrini, F., & Macuco, E. C. (2008). Desenvolvimento da aterosclerose na infância-Artigo de Revisão. Arquivos Brasileiros de Cardiologia, 90(4), 301–308. https://doi.org/10.1590/S0066-782X2008000400012
Wan, H., Huang, T., Yang, P., Wu, T., Zhang, H., & Wu, Q. (2022). Efficacy and Safety of Cilostazol for Atherosclerosis: A Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 79(3), 390–398. https://doi.org/10.1097/FJC.0000000000001195
Weintraub, W. S. (2006). The vascular effects of cilostazol. Canadian Journal of Cardiology, 22(SUPPL. B), 56B-60B. https://doi.org/10.1016/s0828-282x(06)70987-4
Wilhite, D. B., Comerota, A. J., Schmieder, F. A., Throm, R. C., Gaughan, J. P., & Rao, A. K. (2003). Managing PAD with multiple platelet inhibitors: The effect of combination therapy on bleeding time. Journal of Vascular Surgery, 38(4), 710–713. https://doi.org/10.1016/S0741-5214(03)01029-2
Xie, T. Y., Yan, W., Lou, J., & Chen, X. Y. (2016). Effect of ozone on vascular endothelial growth factor (VEGF) and related inflammatory cytokines in rats with diabetic retinopathy. Genetics and Molecular Research, 15(2), 1–11. https://doi.org/10.4238/gmr.15027558
Yoshikawa, T., Mitani, K., Kotosai, K., Nozako, M., Miyakoda, G., & Yabuuchi, Y. (2008). Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. Hormone and Metabolic Research, 40(7), 473–478. https://doi.org/10.1055/s-2008-1065348
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Douglas Felipe Silva; Elise Souza dos Santos Reis; Adriana Yuriko Koga; Diego José Schebelski; Mario Augusto Cray da Costa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
